All Antibody articles – Page 2
-
OpinionThe side effects of being unique
Even the largest clinical trials won’t capture all possible bad reactions to a drug – we need pharmacovigilance
-
BusinessCoronavirus variants stymie success of monoclonal antibodies
Lab-made antibodies can treat and protect people from Covid-19 but are more likely to succeed when administered as a cocktail
-
NewsUK government faces lawsuit over procurement of Covid immunity test
The health department reportedly knew that the antibody test did not perform as well as claimed when it bought them
-
BusinessRegulatory panel unconvinced by Alzheimer’s antibody evidence
US FDA advisors vote against approving Biogen’s aducanumab on the basis of incomplete data analysis
-
OpinionBlood offering
Antibodies in various forms could bridge the Covid-19 treatment gap until a vaccine is available
-
BusinessDrop in plasma donations hits immunoglobulin supply
Lockdown and social distancing have discouraged donors, and the potential impact of convalescent plasma collection for Covid-19 treatment is unclear
-
BusinessWhat are the risks of fast-tracking a Covid-19 vaccine?
Condensing timelines from years to months inevitably involves compromises
-
BusinessCan existing drugs slow Covid-19?
The fastest route to treatments may be to repurpose existing drugs – if they work
-
-
ResearchSmall molecule finds flu virus’s weak spot
Drug candidate that targets highly conserved region of virus gave mice complete protection from swine flu
-
ResearchForceful treatment stabilises drug antibody linkages
Ultrasonic energy could modify maleimide–thiol connections in cancer treatments in volume
-
NewsWhat is directed evolution and why did it win the chemistry Nobel prize?
If you’ve got questions about yesterday’s chemistry Nobel prize then we’ve got answers
-
NewsVaccines central to efforts to head off latest Ebola outbreak
Ring vaccination strategy could halt disease in its tracks provided health systems can cope
-
OpinionRise of the biologics
Antibodies, RNA and gene therapy don’t necessarily compete with small molecule drugs – and they all rely on chemistry
-
BusinessAmgen partners to launch biosimilars in China
US biopharma and Chinese generics firm will co-develop medicines from Amgen’s pipeline focused on inflammation and oncology
-
BusinessAstraZeneca shares tumble after antibody failure
Imfinzi and tremelimumab checkpoint inhibitor pairing fails to beat chemotherapy in lung cancer
-
BusinessCelgene and BeiGene agree cancer partnership
Immuno-oncology deal sees firms exchange licensing rights for antibody drugs
-
BusinessSeattle Genetics cancels Immunomedics deal
Settlement also resolves disputes with shareholders
-
BusinessCholesterol drug withdrawn in patent dispute
Ruling that Regeneron’s Praluent antibody infringes Amgen’s Repatha patent could stifle innovation
-
BusinessStandard antibody will bolster biopharma
New NIST reference material will help validate and compare analytical techniques
- Previous Page
- Page1
- Page2
- Page3
- Next Page